The investigational new drug XK469 induces G2-M cell cycle arrest by p53-dependent and -independent pathways

Clinical Cancer Research

Volumn 7, Issue 11, 2001, Pages 3336-3342

  Ding, Zhenhua ^a   Parchment, Ralph E ^a   LoRusso, Patricia M ^a   Zhou, Jun Ying ^a   Li, Jun ^b,c   Lawrence, Theodore S ^c   Sun, Yi ^b   Wu, Gen Sheng ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (7 CHLORO 2 QUINOXALINYLOXY)PHENOXY]PROPIONIC ACID; GYRASE INHIBITOR; PROTEIN KINASE; PROTEIN P21; PROTEIN P53; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG; XK 469;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; KNOCKOUT GENE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOSIS; MUTATION; NEOPLASMS; QUINOXALINES; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035181262     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Preclinical antitumor efficacy of analogs of XK469: Sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate
2. New in vitro screening model for the discovery of antileukemic anticancer agents
3. Preclinical antitumor activity of XK469 (NSC 656889)
4. XK469, a selective topoisomerase IIß poison
5. Cytotoxic mechanism of XK469: Resistance of topoisomerase IIß knockout cells and inhibition of topoisomerase I
6. Viewpoint: Putting the cell cycle in order
7. Cell cycle control as a basis for cancer drug development
8. WAF1, a potential mediator of p53 tumor suppression
9. Cancer cell cycles
10. 2-phase DNA-damage checkpoint
11. cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2
12. p55CDC25 is a nuclear protein required for the initiation of mitosis in human cells
13. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle
14. Identification of a 95-kDa WEE1-like tyrosine kinase in HeLa cells
15. Mytl: A membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15
16. The human Mytl kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex
17. p53 and chemosensitivity
18. 1 arrest in human cancer cells
19. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
20. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2
21. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity
22. Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugs
23. Loss of function and p53 protein stabilization
24. Participation of p53 protein in the cellular response to DNA damage
25. WAF1/CIP1 expression by p53-independent pathways
26. Physiological regulation of eukaryotic topoisomerase II
27. The p53 pathway
28. Regulation of p53 downstream genes